These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 30622030)
1. Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma. Zhang B; Zhou YL; Chen X; Wang Z; Wang Q; Ju F; Ren S; Xu R; Xue Q; Wu Q Int Immunopharmacol; 2019 Mar; 68():131-136. PubMed ID: 30622030 [TBL] [Abstract][Full Text] [Related]
2. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Yun S; Vincelette ND; Green MR; Wahner Hendrickson AE; Abraham I Cancer Med; 2016 Jul; 5(7):1481-91. PubMed ID: 27167347 [TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer. Xu X; Huang Z; Zheng L; Fan Y Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609 [TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. Devji T; Levine O; Neupane B; Beyene J; Xie F JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543 [TBL] [Abstract][Full Text] [Related]
5. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. Zhang B; Tao B; Li Y; Yi C; Lin Z; Ma Y; Han J; Shao W; Chen Z; Lin J; Chen J Eur J Intern Med; 2023 May; 111():37-46. PubMed ID: 36588054 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials. Hao C; Tian J; Liu H; Li F; Niu H; Zhu B Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143 [TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases. Pires da Silva I; Li I; Ugurel S; Serra-Bellver P; Andhale A; Burnette H; Aya F; Conway JW; Braden J; Carlino MS; Menzies AM; Weichenthal M; Mohr P; Gutzmer R; Arance AM; Johnson DB; Lorigan P; Schadendorf D; Lo SN; Long GV Eur J Cancer; 2024 Jul; 205():114101. PubMed ID: 38735161 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis. An Q; Liu Z BMC Cancer; 2019 Jan; 19(1):43. PubMed ID: 30626368 [TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center. Afzal MZ; Shirai K Melanoma Res; 2018 Aug; 28(4):341-347. PubMed ID: 29750753 [TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study. Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991 [TBL] [Abstract][Full Text] [Related]
12. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. Ugurel S; Röhmel J; Ascierto PA; Flaherty KT; Grob JJ; Hauschild A; Larkin J; Long GV; Lorigan P; McArthur GA; Ribas A; Robert C; Schadendorf D; Garbe C Eur J Cancer; 2017 Sep; 83():247-257. PubMed ID: 28756137 [TBL] [Abstract][Full Text] [Related]
13. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885 [TBL] [Abstract][Full Text] [Related]
14. Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). Wu Y; Ju Q; Jia K; Yu J; Shi H; Wu H; Jiang M Int J Cancer; 2018 Jul; 143(1):45-51. PubMed ID: 29424425 [TBL] [Abstract][Full Text] [Related]
15. Nivolumab: A Review in Advanced Melanoma. Scott LJ Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912 [TBL] [Abstract][Full Text] [Related]
16. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825 [TBL] [Abstract][Full Text] [Related]
17. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Rotte A J Exp Clin Cancer Res; 2019 Jun; 38(1):255. PubMed ID: 31196207 [TBL] [Abstract][Full Text] [Related]
18. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. Tarhini A; McDermott D; Ambavane A; Gupte-Singh K; Aponte-Ribero V; Ritchings C; Benedict A; Rao S; Regan MM; Atkins M Immunotherapy; 2019 Mar; 11(4):283-295. PubMed ID: 30563395 [TBL] [Abstract][Full Text] [Related]